Scynexis Stock Surges on $214 Million Government Contract for Antifungal Drug

Scynexis (NASDAQ: SCYX) shares surged 13.9% in pre-open trading after the company announced it secured a significant contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA). The agreement provides substantial funding for the development of its second-generation antifungal candidate, SCY-247.

The BARDA Partnership

The contract has a potential total value of approximately $214 million if all options are exercised over a possible ten-year period, according to the company's announcement. The initial base period provides $18.5 million to advance both oral and intravenous formulations of SCY-247 into a Phase 2 clinical trial for patients with invasive candidiasis.

Under the cost-sharing agreement, BARDA will cover eligible development costs. If fully executed, the contract could fund the program through to a new drug application (NDA) submission for treating invasive candidiasis and preventing invasive fungal infections in high-risk patients.

Significance for Investors

Ad

A key driver of the stock's rally is the non-dilutive nature of the funding. This means Scynexis can advance a major clinical program without issuing new shares, thereby preventing the dilution of value for existing stockholders—a critical advantage for a clinical-stage biotechnology firm.

The strong upward move in Scynexis stock was a company-specific event, standing in contrast to the broader market, which saw major indices like the S&P 500 and Nasdaq retreat in pre-market trading. The government partnership provides a long-term financial runway and de-risks a significant part of the company's development pipeline.

Strategic Outlook

Scynexis CEO David Angulo, M.D., stated that the partnership addresses "the growing threat of antimicrobial resistance." While pursuing the development of SCY-247, the company also remains focused on its lead rare disease candidate, SCY-770, for autosomal dominant polycystic kidney disease.